From the terminal stage of cancer to the disappearance of the tumor, the 82-year-old Italian uncle only took 1 year, and it was the PD-1 inhibitor that helped him create this miracle, which is a real case reported by the well-known international journal frontier in oncology.
In 2015, Uncle Tai was diagnosed with stomach cancer because of stomach pain, which recurred after surgery, and then chemotherapy failed, and the lesions of liver and abdominal lymph node metastasis became larger and larger, and they were about to go nowhere. At this time, the doctor suggested that he use PD-1 inhibitor treatment, after which the symptoms were gradually alleviated, everything began to improve, and after a year of re-examination, the tumors of the whole body almost disappeared and were completely relieved
Since then, Uncle has insisted on taking medicine, and the tumor has no signs of recurrence. What is PD-1? Does China have such a miracle drug?
<h1 class="pgc-h-arrow-right" data-track="34" >. </h1>
PD-1 inhibitors are tumor immunotherapy drugs, but they are special. It does not act directly on cancer cells, but on the immune cells of the human body. After using PD-1 inhibitors, it can activate the body's own immune system and make the immune cells in the body active to "actively kill the enemy".
PD-1 monoclonal antibody theoretically belongs to the treatment of unlimited cancer species, with a broad spectrum, Li Jin, chairman of the Cancer Clinical Research Committee of the Chinese Association for the Promotion of Medicine, pointed out that whether it is intestinal cancer, stomach cancer, lung cancer or liver cancer and other different cancer species, there is a mismatch to repair the deletion of genes in patients, PD-1 inhibitor treatment may be effective.
Take the world's most famous PD-1 inhibitors, pembolizumab and navulijumab, both of which have more than 2-digit indications, enabling one drug to be effective against multiple cancers.
<h1 class="pgc-h-arrow-right" data-track="33" > second, no limit to cancer, China's anti-cancer must also have a miracle drug! </h1>
At the end of September, the 24th National Clinical Oncology Conference was held in Beijing, at which the research data of a domestically innovative PD-1 monoclonal antibody, slullizumab, received widespread attention.
It is reported that the drug in the clinical study, included the data of 108 tumor patients, including colorectal cancer, stomach cancer, lung cancer and liver cancer and other cancers, these tumor patients have a common point - mismatch repair gene loss, and have experienced radiotherapy, chemotherapy, unfortunately the treatment has failed, has been in a hopeless situation.
After the treatment, the researchers analyzed the patient's data and found that 40% of the patients were effective and safe, and none of the patients had very serious toxic side effects due to the medication, or were disabled or died. In addition, after the patient is medicated, the tumor can no longer develop for more than 5 months, and the patient is still in follow-up, and the survival time without disease progression will be longer.
Li Jin introduced that compared with the PD-1 monoclonal antibody produced in Europe and the United States, the effect of our domestic drugs is not inferior, and even from some aspects, the efficacy is better than that of imported products. Moreover, the price of PD-1 monoclonal antibody independently produced in China is relatively low, and the price after marketing even needs only 1/10 of imported drugs. That is to say, ordinary people only need to spend 1/10 of the price to use the world's top PD-1 monoclonal antibody drugs.
In recent years, China's PD-1 research and development is also in full swing, there are currently a number of drugs approved for listing, and medical insurance has also greatly reduced the burden of patients, to a large number of cancer patients to bring new hope.
<h1 class="pgc-h-arrow-right" data-track="32" > third, inventory of those domestic PD-1 inhibitors</h1>
1. Carellizulizumab: the original price is 19520 yuan / 200mg
Carellizumab is currently approved for the treatment of liver cancer, esophageal cancer, non-squamous small cell lung cancer, and lymphoma. The original price was 19520 yuan / 200mg, and after entering the medical insurance, it achieved an 85% reduction, and the price was 2928 yuan / 200mg.
2. Tirelizumab: the original price is 10900 yuan / 100mg
Tirallizumab is currently approved for the treatment of relapsed, refractory classical Hodgkin lymphoma and locally advanced or metastatic urothelial carcinoma. The original price was 10900 yuan / 100mg, and after entering the medical insurance, it achieved an 80% reduction, and the price was 2180 yuan / 100mg.
3. Triprimumab: the original price is 7200 yuan / 240mg
Triprilimab is currently approved for the treatment of melanoma, the original price was 7200 yuan / 240mg, after entering the medical insurance to achieve a 71% reduction, the price is 2100.97 yuan / 240mg.
4. Xindilizumab: the original price is 7838 yuan / 100mg
Sindili maclizumab is currently approved for the treatment of Hodgkin lymphoma, the original price of 7838 yuan / 100mg, after entering the medical insurance to achieve a 64% reduction, the price of 2843 yuan / 100mg.
<h1 class="pgc-h-arrow-right" data-track="20" > fourth, more and more PD-1 into medical insurance, people can also afford to use "anti-cancer miracle drugs"</h1>
PD-1 has just been developed and launched when the annual cost of treatment is as high as 1 million, and with the advent of more and more new drugs, as well as the improvement of medical insurance, the annual cost of treatment of some PD-1 inhibitors only needs 20,000 yuan, achieving a 50-fold reduction! More and more PD-1s are entering medicare, believing that new drugs have the same opportunity to achieve price reductions.
China has 8 PD-1 inhibitors approved for listing, two of which are imported, 6 are domestic, and 4 have been put into medical insurance. It is believed that in the near future, more and more PD-1 inhibitors will enter the medical insurance and truly realize the vision of affordable anti-cancer drugs. #Health Star Program ##秋季健康不打烊 #
Resources:
[1] "Domestic cancer treatment miracle drugs are coming, these knowledge points you must know". Check out the news.2021.10.1
[2] Was "Anti-Cancer Miracle Drug" PD-1 the Last Straw? 》. Faculty of Pharmacy, First Affiliated Hospital of Wenyi University.2021.4.21
[3] "The new version of the medical insurance directory landed, and the PD-1 monoclonal antibody with an annual fee of more than 100,000 yuan entered the era of 10,000 yuan". Southern Metropolis Daily.2021.3.3
Reproduction without the author's permission is prohibited